

12 November 2014  
EMA/545429/2014  
Committee for Medicinal Products for Human Use (CHMP)  
Committee for Medicinal Products for Veterinary Use (CVMP)

## Agenda of the workshop on the Guideline on pharmaceutical development of medicines for paediatric use

Monday, 01 December 2014, Time: 08:30-17:30, meeting room 3A

Chairpersons: Diana van Riet-Nales and Piotr Kozarewicz

### **Background and objectives**

The Guideline on pharmaceutical development of medicines for paediatric use (Doc. Ref.: EMA/CHMP/QWP/805880/2012 Rev. 2) has been in force as of February 2014 and is intended to provide additional guidance to pharmaceutical developers on quality aspects related with medicinal products for children between birth and 18 years of age.

As more experience becomes available further work is required to complement the guideline with additional recommendations on pharmaceutical development of paediatric medicines.

The general scope of this workshop is to share among stakeholders (regulators, healthcare professionals, academia and industry) experience gained so far with the use of the guideline and identify gaps in the current knowledge which require further elaboration. This workshop should be considered as a starting point for discussing and work towards finding relevant answers to recognised gaps.

### **08:00 - 08.30 Registration**

### **08:30 – 08:45 Welcome and introduction by Workshop Chairs**

---

**Diana van Riet-Nales**, Medicines Evaluation Board (MEB), The Netherlands

**15'**

**Piotr Kozarewicz**, European Medicines Agency (EMA)

---

**08:45 – 10:00 Session 1: Introduction to the Guideline, Paediatric Regulation and Paediatric Investigation Plans (PIPs)**

---

*Paediatric medicines in daily practice* 30'

**Prof Anthony Sinclair**, Birmingham Children's Hospital, United Kingdom

*Paediatric Regulation and PIP procedure* 30'

**Paolo Tomasi**, European Medicines Agency (EMA)

*Questions and discussion* 15'

**Diana van Riet-Nales**, Medicines Evaluation Board (MEB), The Netherlands

---

**10:00 – 10:30 Coffee break**

---

---

**10:30 - 12:45 Session 2: Pharmaceutical development**

---

*Paediatric formulations – principles of development* 30'

**Diana van Riet-Nales**, Medicines Evaluation Board (MEB), The Netherlands

*Formulation issues – regulators perspective* 30'

**Gary Inwards**, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

*Formulation issues – industry perspective* 30'

**Terry Ernest**, GlaxoSmithKline (GSK)

*Container closure system, dosing devices and user information* 30'

**Mirza Ćatibušić**, Health Products Regulatory Authority (HPRA), Ireland

*Questions and discussion* 15'

**Piotr Kozarewicz**, European Medicines Agency (EMA)

---

**12:45 – 13:30 Lunch break**

---

---

**13:30 – 15:15 Session 3: Experience and challenges**

---

*Industry experience from working with the guideline* 30'

**Alecia Barry**, AstraZeneca

*Academia and Paediatric research* 30'

**Prof Joerg Breitzkreutz**, Heinrich-Heine-University Duesseldorf, Germany

*Excipients and paediatric medicines* 30'

**Jean-Marc Vidal**, European Medicines Agency (EMA)

*Questions and discussion* 15'

**Diana van Riet-Nales**, Medicines Evaluation Board (MEB), The Netherlands

---

15:15 – 15:45 Coffee break

---

15:45 – 16:45 Session 4: Next steps

---

*Open session – gap analysis* 30'

All participants

*Next steps* 30'

Piotr Kozarewicz, European Medicines Agency (EMA)

*Questions and discussion* 15'

Piotr Kozarewicz, European Medicines Agency (EMA)

17:00 Closing remarks

---

*Diana van Riet-Nales*, Medicines Evaluation Board (MEB,) The Netherlands

# List of speakers and moderators

---

<b>Alecia Barry</b>	AstraZeneca
<b>Joerg Breitzkreutz</b>	Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University Duesseldorf, Germany
<b>Mirza Ćatibušić</b>	Health Products Regulatory Authority (HPRA), Ireland
<b>Terry Ernest</b>	GlaxoSmithKline
<b>Gary Inwards</b>	Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
<b>Piotr Kozarewicz</b>	European Medicines Agency (EMA)
<b>Diana van Riet-Nales</b>	Medicines Evaluation Board (MEB), The Netherlands
<b>Anthony Sinclair</b>	Birmingham Children's Hospital, United Kingdom
<b>Paolo Tomasi</b>	European Medicines Agency (EMA)
<b>Jean-Marc Vidal</b>	European Medicines Agency (EMA)


# Practical information

## Venue

The European Medicines Agency can be reached:

- **By Docklands Light Railway (DLR)**  
The European Medicines Agency is a short walk from Canary Wharf station on the DLR. Services run from Bank, Tower Gateway, Lewisham, Stratford, King George V and Beckton.
- **By Underground**  
The nearest stop for the European Medicines Agency Westferry Circus is Canary Wharf station on the Jubilee Line.
- **By bus**  
Canary Wharf is serviced by local bus numbers D3, D7, D8, 135 and 277.
- **By boat**  
River services run between Embankment, London Bridge and Canary Wharf throughout the day. Canary Wharf pier is roughly a 15-minute walk from the European Medicines Agency.
- **From London City Airport**  
Take a taxi to Canary Wharf, or catch the DLR to Westferry station then change to the DLR to Canary Wharf.

## Map



## Entering the building

---

The Agency operates a stringent security policy. Upon arrival at ground-floor reception, you will be given a security pass that will allow you to make your way to meeting room 3A on the 3<sup>rd</sup> floor. Tea and coffee will be available on your arrival in the 3<sup>rd</sup> floor foyer.

## Physical disability

---

Let us know if you would like any specific help or information that would make your stay more comfortable. We will be very happy to help.

## Registration

---

We strongly advise you to arrive up to 30 minutes before the start of the workshop, to allow you time for registration and settling down.

## Meeting room

---

You will be able to sit wherever you wish; note that the only reserved seats are for the speakers, panellists and organisers of the workshop.

## Presentations

---

We will not circulate printouts of speakers' presentations. However, you will be able to download them from the Agency's website approximately two weeks after the end of the workshop.

## Laptop computers

---

For those of you travelling from the continent and wishing to use your laptop, may we remind you to bring with you an appropriate UK power adapter.

## Media disclaimer

---

The Agency records or broadcasts a number of its meetings, including some virtual meetings. This is part of the Agency's commitment to the principle of transparency as enshrined in the Treaty on European Union. The Agency herewith informs attendees that this particular meeting will be recorded and broadcast. For more information about processing of personal data by EMA, please visit the website: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/general/general\\_content\\_000516.jsp&mid](http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/general/general_content_000516.jsp&mid) or contact [dataprotection@ema.europa.eu](mailto:dataprotection@ema.europa.eu)

By attending this meeting you consent to any recording or broadcast.

## Conference venue and secretariat

---

30 Churchill Place, Canary Wharf  
London E14 5EU, United Kingdom

**Tel.:** +44 (0)20 3660 6000

**Fax:** +44 (0)20 3660 5555

**E-mail** [Marta.Jakimiuk@ema.europa.eu](mailto:Marta.Jakimiuk@ema.europa.eu)/ [Simona.Keckesova@ema.europa.eu](mailto:Simona.Keckesova@ema.europa.eu)

**Website** [www.ema.europa.eu](http://www.ema.europa.eu)